Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report

INTRODUCTION: Tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) are approved for use in metastatic non-small cell lung cancer (NSCLC). CASE PRESENTATION: Here we present a case of a African American patient with stage IIIA NSCLC treated with osimertinib in the neoadj...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Caroline Y., Fares, Charlene M., Shin, Daniel Sanghoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066434/
https://www.ncbi.nlm.nih.gov/pubmed/33892800
http://dx.doi.org/10.1186/s13256-021-02748-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066434/
https://www.ncbi.nlm.nih.gov/pubmed/33892800
http://dx.doi.org/10.1186/s13256-021-02748-y

Ejemplares similares